Table 3.
Characteristics of the studies in meta-analysis.
| Study | Year | Country | Journal | Study type | Level of evidence | Sample size(E/C) * | Gender (M/F)* | Median age (E/C) | Intervention(E) | Intervention(C) |
|---|---|---|---|---|---|---|---|---|---|---|
| Morelli7 | 2005 | Rome | Intensive Care Med | RCT | I | 15/13 | 21/7 | 62.4 /61.5 | Levosimendan | Dobutamine |
| Morelli14 | 2010 | Rome | BioMed Central | RCT | I | 20/20 | 30/10 | 68.0/66.0 | Levosimendan | Dobutamine |
| Fang15 | 2014 | China | Chin Crit Care Med | RCT | I | 18/18 | 27/9 | 61.4/61.7 | Levosimendan | Dobutamine |
| Meng16 | 2016 | China | Med Sci Monit | RCT | I | 19/19 | 24/14 | 55.4/50.2 | Levosimendan | Dobutamine |
| Hajjej17 | 2017 | Tunis | Shock | RCT | I | 10/10 | 17/3 | 51.0/ 61.0 | Levosimendan | Dobutamine |
| Xu18 | 2018 | China | Chin J Intern Med | RCT | I | 15/15 | 16/14 | 87.9/88.1 | Levosimendan | Dobutamine |
E experimental group; C controlled group; RCT randomized controlled trials.